Leading Edge Gamma Knife Radiosurgery

The leading edge technique is an innovative process developed to treat one of the most common types of glioma, glioblastoma multiforme. The leading edge treatment combines the functionality of the Gamma Knife radiosurgery technology with the advances in diagnostic radiology technology, which include Multivoxel MR-Spectroscopy scans. This unique combination targets the radiation beyond the local tumor volume to include the potential malignant tumor path. Prior to this technological spectroscopy breakthrough, it was impossible to detect where the tumor would or might spread.

CLINICAL EXPLANATION

Glioblastoma multiforme (GBM) is among the most common and devastating brain tumors affecting adults. The most successful treatment regimens for GBMs include surgical resection, radiation therapy and chemotherapy, followed by stereotactic radiosurgical boost (Gamma Knife radiosurgery) and immunotherapy. Despite aggressive therapies, the malignant nature of GBMs often results in tumor recurrence. Ninety percent of GBMs recur at the site of the original tumor. In addition to local recurrence, malignant gliomas frequently spread in predictable patterns along the white matter pathways in the brain. It is via this mechanism that long-fought battles against GBMs are often lost.

Spread in Malignant Gliomas

Predictable Patterns of Spread in Malignant Gliomas

Traditional radiosurgical techniques have focused solely on local tumor margins, as determined by gadolinium enhancement on MRI. However, recent data suggests that by targeting the “leading edge” of these tumors, their spread along white matter pathways can be more effectively halted. FLAIR sequences and Multivoxel MR-Spect scans can be utilized to define positive areas outside of the gadolinium T1-weighted enhancing zones. Targeting these zones with gamma knife is proving to be a successful method of blocking the path of malignant gliomas.

Targeting of MR-Spect

Targeting of MR-Spect positive zones outside of Gadolinium T1-weighted enhancing zones

Neoplastic Brain Regions

MR-Spectrography of normal and neoplastic brain regions

Normal Areas From Tumor

Multivoxel MRS can distinguish normal areas from tumor

Glioblastoma Multiforme

Initial results are optimistic, with a mean follow-up from diagnosis of 14.4 months (range = 2 to 58 months), and mean follow-up from the time of radiosurgery of 8.4 months (range = 1 to 24 months). Median projected Kaplan-Meier survival was 22 months for patients receiving leading edge therapy as their primary treatment, 15.5 months for patients with recurrent disease, and 23 months from the time of diagnosis for all patients.

Longer follow-up is necessary to determine the overall efficacy of “leading edge” radiosurgery. But these data suggest that targeting the white matter pathways along which GBMs are known to spread results in a survival advantage for patients with these aggressive, malignant gliomas.

In our series, 18 consecutive patients with amenable tumors (i.e. lobar, polar locations) were treated with our “leading edge” Gamma Knife procedure. Ages ranged from 21 to 72 years (median = 49). Eight of the 18 patients were being treated for recurrent disease. Most had received some form of prior treatment, including LAK cell therapy (6), chemotherapy (8) and prior GK treatments (3). However, no statistical difference was observed among these groups. Complications were comparable to those seen with traditionally radiosurgical targeting, and included a 44% mild edema rate requiring short-term steroid therapy, and 5% admission rate for mannitol and IV steroids for severe edema and radiation necrosis


Learn about the "Leading Edge©" Gamma Knife technigue.  Read article.


If you wish to make a consultation appointment with Dr. Duma, or for further information about our "leading edge" Gamma Knife radiosurgery programs, please register on our website. Also, you can reach us at 949-642-6787.

Improving
Quality of LifeRequest an appointment

Testimonials

'I was given a couple of months to live. Dr Duma is brilliant.'

Eric Muranaka
Malignant Brain Tumor
8 year survivor

'Thanks to Dr. Duma, my brain tumor has completely diminished.'

Victor Pimenta
Anaplastic Astrocytoma
14 year survivor

'He was knowledgeable and patient when addressing my concerns!'

Allison Smith-Conway
Parkinson's Disease
Symptom free 2 years

'I am alive today because of Dr. Duma.'

Lindsay Susskind
Glioblastoma Multiform
6 year survivor

'The standard of care Dr. Duma offers is stellar. '

Paul Roberts
Glioblastoma Multiform
6 year survivor

'You have extended my life, not only in time, but also the quality of life.'

Richard Teter
Glioblastoma Multiform
2 year survivor

'He is always concerned for my well-being. I trust him with my life!'

Kathy Hyams
Breast Cancer Brain Metastases
10 year survivor

Dr. Duma Patented Radio Surgery